There are new expansion plans in the gold mine: Mainz-based company Biontech also wants to research and manufacture in Australia in the future. It’s also about new cancer treatments.
Following its success with the corona vaccine, Mainz-based pharmaceutical company Biontech is further expanding its international presence by building a research center and a manufacturing facility in Australia. One focus should be on the research of cancer treatments.
The company said on Friday that Biontech has agreed on a strategic collaboration with the Australian state of Victoria to collaborate in the research and development of potential mRNA-based vaccines and treatments. mRNA technology has already been successfully used in Biontech’s Corona vaccine.
Biontech wants to speed up cancer treatments
The jointly operated research center will be built in Melbourne. It primarily aims to support scientists in the implementation of research projects in clinical development.
In addition, Biontech plans to expand clinical research capabilities in Australia and include additional study centers to accelerate the development of therapeutic options for cancer. According to the company, Biontech’s pipeline consists of a total of 18 product candidates in 23 clinical trials currently underway.
Third own mRNA production facility outside Germany
Additionally, the company aims to support the establishment of a clinical-scale mRNA production facility for a wide variety of clinical programs. Production containers called “BioNTainers” will also be built at the Melbourne site. The Australian city will thus become the company’s third own mRNA production facility outside of Germany.
The company has already announced the establishment of such production facilities in Africa, for example in Rwanda and Singapore.